Trials / Unknown
UnknownNCT05101135
To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
This Study Evaluates the Addition of Dapagliflozin in the Treatment of Type 2 Diates With Metformin and JT-001 Combination Therapy.
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 256 (estimated)
- Sponsor
- Jeil Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of JT-001 Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JT-001 | Subjects take the investigational products once a day for 24 weeks. |
| DRUG | JT-001 Placebo | Subjects take the investigational products once a day for 24 weeks. |
Timeline
- Start date
- 2021-11-17
- Primary completion
- 2022-10-31
- Completion
- 2022-10-31
- First posted
- 2021-11-01
- Last updated
- 2022-03-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05101135. Inclusion in this directory is not an endorsement.